Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Observational 2Interventional 1

Sponsor

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Muscle-Invasive Bladder Carcinoma × Clear all
NCT05295992 2026-03-06

ARTIA-Vesica

Varian, a Siemens Healthineers Company

Phase NA Active not recruiting
110 enrolled

Muscle-Invasive Bladder Carcinoma

NCT05028660 2025-05-09

AUR93A

Elypta

Completed
43 enrolled

Muscle-Invasive Bladder Carcinoma

NCT05221827 2023-02-27

Clinical Performance Evaluation of the C2i-Test

C2i Genomics

Terminated
3 enrolled

Muscle-Invasive Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡